Sanofi Aventis news from FiercePharma
NewsSanofi launches $1.92B Zentiva offer
Make way for Sanofi-Aventis. The French pharma has officially launched a $1.92 billion counterbid for Zentiva, the Czech generics maker. It's a 14.6 percent premium over Zentiva's closing price the... Read more...
Setback for Lilly, gain for Plavix?
SPOTLIGHT: Setback for Lilly, gain for Plavix?When FDA delayed its decision on Eli Lilly's clot-buster prasugrel, a.k.a. Effient, it sliced at least three months off the time Lilly might have to win... Read more...
Sanofi confirms sales rep layoffs
It's been rumored for weeks, and now Sanofi-Aventis is confirming. Yes, the French drugmaker will cut jobs at home in France. Details are sketchy, but here's what we know: Sanofi will lay off 700 to... Read more...
| Press ReleasesPRESS RELEASE: Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine SWIFTWATER, Pa., and LYON, France, Nov. 7 -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, Read more >> PRESS RLEASE: Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis TARRYTOWN, N.Y. -- Aug 23, 2007 - Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the Read more >> |
Get more Sanofi Aventis coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
